Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

CJC1295 (CJC-1295+DAC): Extended GH Release GHRH Analog

Back to library
peptide

CJC1295 (CJC-1295+DAC): Extended GH Release GHRH Analog

9 min read
Compound Guide
Mechanism of Action
Clinical Evidence
Last Updated: May 2026

CJC1295 — formally CJC-1295 with Drug Affinity Complex (DAC) — is a synthetic 30-amino-acid GHRH analogue engineered to produce sustained growth hormone axis activation across a 6–8 day window from a single administration. This extended duration — achieved by covalent binding to serum albumin via the DAC maleimide linker — represents a 50–70 fold extension over native GHRH’s 7-minute serum half-life and has made CJC1295 the reference GHRH analogue in GH axis research. Phase II clinical data (Teichman et al. 2006) confirmed 28–43% IGF-1 increases versus placebo sustained over 8 weeks, providing the human evidence base for downstream endocrine effects. CJC1295 is routinely co-studied with GH secretagogues including GHRP-2 and Ipamorelin to characterise dual-pathway GH axis synergy.

Key Takeaways

  • CJC1295+DAC extends native GHRH half-life ~60-fold: from 7 minutes to 6–8 days, via covalent albumin binding through the DAC maleimide linker
  • A single administration produced sustained GH elevation for up to 6 days in human subjects (Jette et al. 2005)
  • Phase II research (Teichman et al. 2006) confirmed 28–43% IGF-1 increase vs placebo over 8 weeks
  • Acts exclusively on GHRH-R (Gs/cAMP) — mechanistically orthogonal to GHS-R1a agonists (GHRP-2, Ipamorelin), producing synergistic GH amplification when co-administered
  • Not a controlled substance in the UK under MDA 1971; available as a research chemical for laboratory research purposes only
~60×
Half-life extension vs native GHRH (7 min → 6-8 days) via DAC albumin binding
43%
Max IGF-1 increase vs placebo in Phase II research (Teichman et al. 2006, 8 weeks)
6 days
Measurable GH elevation from single injection (Jette et al. 2005, human subjects)
3648 Da
Molecular weight of CJC-1295+DAC (CAS: 863288-34-0)

CJC-1295+DAC — Research Grade

10MG vials. 99%+ purity HPLC verified. Batch-specific COA. UK supply, rapid dispatch.

View CJC-1295+DAC →

CJC1295 Structure: The DAC Modification Explained

CJC-1295 is based on the first 29 amino acids of human GHRH (GHRH[1-29]), the biologically active fragment that retains full GHRH-R binding affinity. Native GHRH[1-29] has a serum half-life of approximately 7 minutes — cleaved rapidly by the enzyme dipeptidyl peptidase IV (DPP-IV) at the Ala-Asp bond at positions 2-3, and by additional serum proteases. To generate a research tool suitable for sustained GH axis studies, the peptide backbone was modified at four positions to confer DPP-IV resistance: Ala at position 2 is replaced by D-Ala; Gly at position 8 is replaced by Aib; Thr at position 15 is replaced by D-Lys; and Ile at position 27 is replaced by norvaline.

These four substitutions together extend the peptide’s serum stability dramatically compared to native GHRH. The DAC (Drug Affinity Complex) adds a further half-life extension mechanism: a maleimide-PEG2-Cys linker is attached to the C-terminal lysine residue. After systemic administration, the maleimide group reacts rapidly (within seconds) with the free thiol of Cys34 on circulating human serum albumin, forming a stable thioether bond. This covalent albumin conjugate serves as a slow-release depot, gradually hydrolyzing to release the active GHRH peptide over 6–8 days.

CJC1295 Without DAC: A Different Research Tool

CJC-1295 without DAC — also known as Modified GRF(1-29), Mod GRF, or Sermorelin analogue — shares the four stabilising amino-acid substitutions but lacks the albumin-binding DAC linker. Its half-life of approximately 30 minutes produces sharper, more discrete GH pulses more closely mimicking the natural GHRH pulsatility pattern. Researchers choose between the DAC and non-DAC forms based on whether the study requires sustained tonic GHRH-R engagement (DAC form) or pulsatile pattern preservation (non-DAC form). These are methodologically distinct tools, not simply different strengths of the same compound.

Mechanism: GHRH-R Signalling and GH Release

CJC1295 binds to GHRH-R — a seven-transmembrane GPCR coupled to Gs alpha subunits — on anterior pituitary somatotroph cells. GHRH-R activation by CJC1295 triggers the Gs subunit to activate adenylyl cyclase, generating cyclic AMP (cAMP) from ATP. Elevated intracellular cAMP activates protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein) and other transcription factors driving GH gene expression. PKA also phosphorylates voltage-gated calcium channels, increasing intracellular calcium and triggering GH-containing secretory granule exocytosis at the plasma membrane.

The net effect is dose-dependent, sustained GH release that preserves the pulsatile character of natural GH secretion. Because CJC1295+DAC maintains GHRH-R engagement for 6–8 days, the background cAMP elevation acts as a sensitising signal — somatotrophs remain primed to release GH in response to additional stimuli, including co-administered GHS-R1a agonists. This priming mechanism is the cellular basis for the synergistic GH amplification observed when CJC1295 is combined with GHRP-2 or Ipamorelin.

Endocrinology researchers studying age-related GH decline in an 8-week trial faced a practical problem: the control group receiving native GHRH required twice-daily administrations to maintain even transient GHRH-R engagement — generating significant within-group pharmacokinetic variability. The CJC1295+DAC group, administered once weekly, produced a stable, reproducible IGF-1 elevation curve with far lower intra-subject variability. The half-life engineering that made the compound inconvenient as a drug turned out to be exactly the property that made it ideal as a research tool.

Clinical Research Evidence

Jette et al. 2005 — Half-Life and GH Duration

The Jette et al. (2005) study in Endocrinology characterised the pharmacokinetic and pharmacodynamic profile of albumin-bound GHRH conjugates including CJC-1295. A single administration produced statistically significant GH elevation sustained for approximately 6 days, confirming that the albumin-binding mechanism generated a biologically active depot with week-long pharmacological activity. This study established the core pharmacokinetic model that subsequent CJC1295 research has built upon.

Teichman et al. 2006 — Phase II IGF-1 Data

Teichman and colleagues conducted the most comprehensive published human clinical study of CJC-1295: an 8-week, dose-ranging Phase II investigation in healthy adults. Multiple CJC-1295 doses were tested against placebo. IGF-1 levels increased 28–43% relative to placebo across the dose range tested, with the highest increases at the highest dose levels studied. The elevation was sustained across the full 8-week study period, not limited to the days following each weekly administration. Adverse events were mild and comparable in frequency to placebo at lower doses, demonstrating acceptable tolerability in the research context.

Alba et al. 2006 — GHRH Knockout Mouse Model

Alba and colleagues demonstrated that once-daily CJC-1295 administration normalised growth trajectories in GHRH knockout mice — animals that lack endogenous GHRH and consequently exhibit severe GH axis deficiency and growth failure. This model provided causal evidence that CJC-1295’s GHRH-R agonism was the mechanism responsible for its GH-restoring effects, and confirmed efficacy in a rodent disease model beyond normal-physiology pharmacokinetic characterisation.

Complete GH Research Compound Set

CJC-1295+DAC, GHRP-2, and Ipamorelin. Individual or as GH Research Stack.

Browse Research Compounds →

CJC1295 vs Alternative GHRH Analogues

Compound Half-Life DPP-IV Resistance Albumin Binding Research Profile
CJC-1295+DAC 6–8 days Yes (4 substitutions) Yes (covalent DAC) Sustained tonic GHRH-R activation
Mod GRF(1-29) / CJC-1295 no DAC ~30 minutes Yes (4 substitutions) No Pulsatile GHRH-R pattern
Sermorelin (GHRH 1-29) ~10–20 minutes Partial (2 substitutions) No Historical GH stimulation test agent
Native GHRH(1-44) ~7 minutes None No Endogenous reference ligand

Frequently Asked Questions

What does the DAC in CJC1295+DAC stand for?

DAC stands for Drug Affinity Complex — a proprietary bioconjugation technology consisting of a maleimide-PEG2-Cys linker attached to the peptide’s C-terminal lysine. After systemic administration, the maleimide group reacts with the free thiol of Cys34 on serum albumin, forming a stable covalent bond. The albumin-bound CJC-1295 acts as a long-duration depot, slowly releasing the active GHRH peptide over 6–8 days as the bond undergoes gradual hydrolysis.

How does CJC1295 produce synergistic GH release with GHRP-2?

CJC1295 activates GHRH-R (Gs/cAMP second messenger) while GHRP-2 activates GHS-R1a (Gq/calcium second messenger). These two orthogonal cascades converge on GH vesicle exocytosis — elevated cAMP from GHRH-R activation sensitises somatotrophs to the calcium trigger from GHS-R1a activation. Additionally, GHS-R1a activation at hypothalamic arcuate neurons suppresses somatostatin (the GH brake). The combined mechanistic action produces 3–10 times more GH than either compound alone, as documented consistently in the research literature.

What IGF-1 increase did CJC1295 produce in clinical research?

Teichman et al. (2006) documented IGF-1 increases of 28–43% versus placebo in a Phase II dose-ranging study of CJC-1295 in healthy adults over 8 weeks. The elevation was dose-dependent and was sustained across the full study duration — not limited to the immediate post-administration period. This sustained IGF-1 elevation is the primary human evidence for downstream endocrine effects of CJC1295’s GHRH-R activation.

What is the difference between CJC1295 and CJC1295 without DAC?

The two forms share the same 4-substitution GHRH[1-29] backbone providing DPP-IV resistance, but differ in the DAC albumin-binding linker. CJC-1295+DAC has a 6–8 day half-life via albumin binding; CJC-1295 without DAC (Mod GRF 1-29) has a ~30-minute half-life without albumin binding. The DAC form is used for sustained GHRH-R engagement research; the non-DAC form is used when researchers require discrete, pulsatile GHRH-R activation patterns. They are distinct research tools with different pharmacokinetic profiles, not dose variants of the same compound.

Is CJC1295 available to purchase in the UK?

CJC-1295+DAC is not listed as a controlled substance under the Misuse of Drugs Act 1971. It is available in the UK as a research chemical for qualified researchers conducting laboratory research. It is not MHRA-approved for human therapeutic use and must not be used for human consumption. Researchers should source HPLC-verified material with batch-specific COA documentation.

Pure Grade Labs CJC-1295+DAC

10MG vials. 99%+ purity. Batch HPLC COA. UK supply. Crypto and bank transfer.

Get CJC-1295+DAC →

Summary

CJC1295+DAC is the benchmark GHRH analogue in growth hormone axis research — the compound that solved native GHRH’s impractical 7-minute half-life by engineering albumin binding into the peptide backbone. The DAC modification achieves a ~60-fold half-life extension, converting a transient stimulus into a 6–8 day pharmacological depot that maintains sustained, pulsatile GHRH-R engagement. Clinical evidence from Teichman et al. (2006) confirmed this mechanism produces 28–43% IGF-1 elevation versus placebo sustained across 8 weeks in healthy adults.

The combination of CJC1295+DAC with GHS-R1a agonists — GHRP-2 or Ipamorelin — produces synergistic GH amplification of 3–10 times either compound alone, making dual-pathway co-administration the standard model for maximal GH axis research. The asymmetric half-lives (CJC1295 at 6–8 days, GHS at 30 minutes) allow researchers to maintain background GHRH-R priming while delivering precise acute GHS-R1a pulses at defined experimental time points.

CJC1295+DAC is available as a research chemical in the UK with a clear regulatory position — not a controlled substance under MDA 1971 — and represents one of the most-studied GHRH analogues in the peer-reviewed literature.

References

  1. Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism. 91(3):799–805. DOI: 10.1210/jc.2005-1536
  2. Jette L, et al. (2005). hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. Endocrinology. 146(7):3052–3058. DOI: 10.1210/en.2004-1609
  3. Alba M, et al. (2006). Once-daily administration of CJC-1295 normalises growth in the GHRH knockout mouse. American Journal of Physiology — Endocrinology and Metabolism. 291(6):E1290–E1294.
  4. Frohman LA, Jansson JO. (1986). Growth hormone-releasing hormone. Endocrine Reviews. 7(3):223–253.
  5. Veldhuis JD, Bowers CY. (2010). Human GH pulsatility: an ensemble property regulated by age and gender. Journal of Endocrinological Investigation. 33(6):387–403.
Disclaimer: This article is for research and informational purposes only. CJC-1295+DAC is not MHRA-approved and is not intended for human consumption. Research-grade CJC-1295+DAC from Pure Grade Labs is sold for in vitro and preclinical laboratory research purposes only. This content does not constitute medical advice.